Julian Blagg, Paul Workman
Index: 10.1016/j.ccell.2017.06.005
Full Text: HTML
Small-molecule chemical probes or tools have become progressively more important in recent years as valuable reagents to investigate fundamental biological mechanisms and processes causing disease, including cancer. Chemical probes have also achieved greater prominence alongside complementary biological reagents for target validation in drug discovery. However, there is evidence of widespread continuing misuse and promulgation of poor-quality and insufficiently selective chemical probes, perpetuating a worrisome and misleading pollution of the scientific literature. We discuss current challenges with the selection and use of chemical probes, and suggest how biologists can and should be more discriminating in the probes they employ.
HDAC Inhibitors Finally Open Up: Chromatin Accessibility Sig...
2017-07-10 [10.1016/j.ccell.2017.06.008] |
Redefining Hormonal Therapy for Advanced Prostate Cancer: Re...
2017-07-10 [10.1016/j.ccell.2017.06.007] |
MUC-king with HIF May Rewire Pyrimidine Biosynthesis and Cur...
2017-07-10 [10.1016/j.ccell.2017.06.006] |
MUC1 and HIF-1alpha Signaling Crosstalk Induces Anabolic Glu...
2017-07-10 [10.1016/j.ccell.2017.06.004] |
Tumor Evolution of Glioma-Intrinsic Gene Expression Subtypes...
2017-07-10 [10.1016/j.ccell.2017.06.003] |
Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer
Copyright © 2024 ChemSrc All Rights Reserved